Navigation Links
New collaboration to develop treatments for liver disease
Date:9/7/2012

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

The partnership, between the University and global pharmaceutical company GlaxoSmithKline (GSK), will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in a population of patients with a particular mutant gene.

Alpha-1 antitrypsin (A1AT) deficiency is one of the most common genetic disorders in the UK, affecting approximately one in 2,000 people. The A1AT protein is produced mainly in the liver and circulates to the lungs, where it serves a protective function against enzymes which can break down lung tissue.

In patients with A1AT deficiency, the protein cannot circulate freely and accumulates in the liver, leading to potentially life-threatening liver conditions including neonatal hepatitis, cirrhosis and hepatocellular carcinoma. Additionally, without A1AT circulating to the lungs, lung tissue can break down, predisposing patients to early onset emphysema. Currently, the only available treatments are liver transplantation for cirrhosis and protein replacement therapy for emphysema.

The mechanism that underlies protein accumulation in the livers of individuals with A1AT deficiency has been defined by the team led by Professor David Lomas in the University's Cambridge Institute for Medical Research (CIMR). The collaboration with GSK will combine Professor Lomas' long-term research with GSK's expertise in drug discovery and development in order to develop new therapeutics. Work on the project will be carried out both at GSK and at the CIMR.

"Currently, the only option for patients with liver disease as a result of alpha-1 antitrypsin deficiency is transplantation," said Professor Lomas. "This partnership brings together our collective expertise in target biology and drug discovery to tackle an unmet medical need and by teaming up with GSK, we have a great opportunity to turn our research into effective treatments."

This alliance is part of GSK's Discovery Partnerships with Academia (DPAc) initiative, designed to bring together the complementary skill sets of GSK and individual academic groups in the search for new medicines. Dr Pearl Huang, who leads GSK's Global DPAc, said, "Through this collaboration, we'll be able to combine the substantial knowledge and insight of the Cambridge University scientists working in this field with GSK's drug discovery expertise. By combining our strengths in this way and creating an integrated partnership we will have in place a strong framework for discovering new medicines for patients."

Dr Emma Barker of Cambridge Enterprise, the University's commercialisation group said: "This is a great example of translating academic research. We are delighted to be involved with GlaxoSmithKline's DPAc alliance with the goal of developing & commercialising medicines to treat a clear unmet medical need."

Under the terms of the agreement, the University and Cambridge Enterprise will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialised out of the collaboration.

Professor Lomas' research is funded by the Medical Research Council (MRC).


'/>"/>

Contact: Sarah Collins
sarah.collins@enterprise.cam.ac.uk
44-122-376-0335
Cambridge Enteprise University of Cambridge
Source:Eurekalert

Related medicine news :

1. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
2. Treating the whole person with autism sets direction for parent-clinician collaboration
3. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
4. Researchers develop a new cell and animal model of inflammatory breast cancer
5. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. Kudos for 3 NJIT Enterprise Development Center high-tech companies
8. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
9. Online Tool Could Diagnose Autism Quickly, Developers Say
10. Discovery could help to develop drugs for organ transplant and cancer patients
11. 2 repressor genes identified as essential for placental development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 2016 , ... Mental health watchdog Citizens Commission on Human Rights (CCHR) ... of psychiatry Thomas Szasz, is continuing its protest against the use of electroshock (ECT) ... Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest at the annual ...
(Date:5/24/2016)... ... 24, 2016 , ... Boyd Industries, a leading supplier of dental chairs ... product for pediatric dentistry , at AAPD 2016, the annual conference and trade ... The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the ...
(Date:5/24/2016)... San Mateo, CA (PRWEB) , ... May 24, ... ... society dedicated to advancing the science and clinical practice of radiosurgery, is recognizing ... fields of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, ... first penis transplant in the United States . The 64-year-old patient who received the ... The transplant could restore not only a natural appearance, but also urinary and sexual ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, the consumer ... will deliver a new series of Q&A videos to clinicians and patients at ... expertise of Harvard Medical School faculty into brief videos that clinicians using vidscrip ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Cellvizio Highlighted in Physician ... Meeting and 91 st Congress of the ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... that its Cellvizio platform is being highlighted at ... the month of May. The first meeting highlighting ...
(Date:5/19/2016)... According to a new market research report ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is ... of 13.9% from 2016 to 2021.      (Logo: ... Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology: